Chitavi (Chloe) Maulloo, Ph.D. Email & Phone Number
@uchicago.edu
LinkedIn matched
Who is Chitavi (Chloe) Maulloo, Ph.D.? Overview
A concise factual answer block for searchers comparing this professional profile.
Chitavi (Chloe) Maulloo, Ph.D. is listed as IMBA Candidate at IE Business School, a with 3674 employees, based in New York, United States. AeroLeads shows a work email signal at uchicago.edu and a matched LinkedIn profile for Chitavi (Chloe) Maulloo, Ph.D..
Chitavi (Chloe) Maulloo, Ph.D. previously worked as Biotech and Pharma Equity Research Associate at Scotiabank - Global Banking And Markets and Biotech & Pharma Equity Research Associate at Scotiabank - Global Banking And Markets. Chitavi (Chloe) Maulloo, Ph.D. holds Molecular Engineering, Immunology, Lymphatics from University Of Chicago.
Email format at IE Business School
This section adds company-level context without repeating Chitavi (Chloe) Maulloo, Ph.D.'s masked contact details.
AeroLeads found 1 current-domain work email signal for Chitavi (Chloe) Maulloo, Ph.D.. Compare company email patterns before reaching out.
About Chitavi (Chloe) Maulloo, Ph.D.
Immuno-engineering scientist, founder, and equity research professional looking to apply my subject matter expertise in biotechnology and drug development, analytical, financial modeling, communication, and leadership skills, as well as experience in venture creation and deal support (opportunity sourcing and assessment, valuation, IP agreements, go/no-go decision-making, strategic partnerships) to the following roles:- biotech analyst/ investor in public or private equities or venture capital- business development and portfolio strategy in biotech or pharma- corporate communications and investor relations in biotech- technology licensing and venture creation in academia
Listed skills include Cancer Immunology, Nanoparticles, Inorganic Synthesis, Lymphatics, and 28 others.
Chitavi (Chloe) Maulloo, Ph.D.'s current company
Company context helps verify the profile and gives searchers a useful next step.
Chitavi (Chloe) Maulloo, Ph.D. work experience
A career timeline built from the work history available for this profile.
Biotech And Pharma Equity Research Associate
Biotech & Pharma Equity Research Associate
CurrentBuilding Scotiabank's U.S. biotech and pharma franchise with seasoned analyst, George Farmer
Senior Associate In Biotech Equity Research
Coverage (Genetic Medicine and Precision Oncology): ACHL, CABA, CRSP, EDIT, IMTX, IOVA, IPSC, KRYS, MGTX, MRNA, NTLA, PASG, PDSB, PRVB, RCKT, SNTI, SQZ, TNYA, TSHA, VYGR▪ Conducted due diligence and market research on public and private companies in the space including deal analysis (collaborations, licensing, acquisitions), clinical trial, IP, and regulatory landscape analysis, and 20+ KOL interviews ▪ Synthesized and communicated science-driven investment theses in gene editing, cell and gene therapy in >80 written research reports and in oral pitches, including competitive landscape analysis on developing drug candidates▪ Built >5 financial models including scenario and sensitivity analyses to forecast commercial performance using research-driven market sizing, demand, penetration, competition, patient experience and drug pricing assumptions ▪ Led cross-team biweekly meetings, collaborated on, and tracked deliverables for >30 reports on gen med advances
Senior Associate In Biotech Equity Research
Coverage (Immunology, Oncology, Nephrology, and Rare Disease): KZR, BCRX, CMPI, IDYA, KALV, RZLT, SLDB, TYRA, TCON, AYLA; familiar with AFMD, ALNY, AUPH, CALT, CMRX, DTIL, EIGR, EPIX, FMTX, KPTI, MRTX, MRUS, RARE, SGMO, SRRA, THRX, TVTX, VALN▪ Performed scientific, clinical, and financial due diligence on coverage, including primary research via KOL interviews ▪ Vetted investment banking deals, developed business case, resulting in 2 “go” recommendations and ~$300 million in primary and secondary offerings (TYRA, RZLT) and 2 “no-go” decisions due to outstanding questions around mechanism of action, differentiation from competitors, efficacy/ safety profile and translatability of preclinical data ▪ Synthesized and communicated investment theses and recommendations in >100 written reports and presentations ▪ Built >7 financial models for pipeline valuation and updated >40 models based on companies’ earnings releases
Originator And Lead, Phlaxis
▪ Assembled and managed team, developed and pitched value story, and forecasted peak revenue of $1.7 billion▪ Managed and authored business, scientific and regulatory docs including pitch decks, patents, grants, manuscripts▪ Performed primary research, via 30+ interviews of stakeholders including industry experts, KOLs, payers, physicians, and parents of food allergic children to understand unmet need in patient population (NSF I-Corps program)▪ Designed novel framework/ go-to-market strategy for introducing food allergy vaccination in high-risk pediatric population▪ Integrated research into actionable insights to optimize vaccine design and implement risk-mitigation strategies ▪ Raised $280k via the Deep Tech Compass Accelerator and competitive Edward L. Kaplan New Venture Challenge
Phd Candidate
Advisors: Dr. Jeffrey Hubbell, Dr. Melody Swartz▪ Designed a novel biomaterial-based protein delivery system which can be used to induce a targeted and suppressive immune response (inverse vaccine) with applications in the prevention and treatment of autoimmunity and allergies▪ Developed strategic partnerships with academic collaborators and industry partners (Anokion) to advance project▪ Authored Food Allergy Fund Innovators Research Grant which led to $100k in funding in 2020▪ 1st author publication: Maulloo CD, Cao S, Watkins EA, Raczy MM, Solanki AS, Nguyen M, Reda JW, Shim H-N, Wilson DS, Swartz MA and Hubbell JA (2021) Lymph Node-Targeted Synthetically Glycosylated Antigen Leads to Antigen-Specific Immunological Tolerance. Front. Immunol. 12:714842. doi: 10.3389/fimmu.2021.714842
Teaching Assistant And Lecturer
Teaching Assistant and Lecturer, The Engineering and Biology of Tissue Repair (Spring 2017)-Led biweekly literature review sessions, exam review sessions, guided graduate and undergraduate students through proposal writing projects, wrote exam questions and graded them for 15-20 students-Taught a lecture on “Skin and Lymphovascular Engineering”Teaching Assistant, Cellular Engineering (Winter 2017)-Led biweekly class material review workshops, guided research project proposals, graded problem sets and exams for 25-30 students
Life Sciences Analyst
▪ Conducted scientific/ financial diligence on public smidcap biotech companies in oncology and respiratory disease ▪ Communicated investment theses and recommendations to portfolio manager in 4 reports and 8 presentations
Undergraduate Researcher
Advisor: Dr. Lisa DeLouise-Characterized and optimized the surface chemistry, and particle stability of Zinc Sulfide quantum dots-Established an on-campus collaboration with Professor Todd Krauss to synthesize the quantum dots-Investigated the coating of mesoporous silica nanoparticles with polyethylinimine and siRNA as a gene-silencing tool
Chemistry Workshop Leader
Workshop Leader in these following courses: Quantum Chemistry, Physical Chemistry, Inorganic Chemistry, Honors Organic Chemistry-Led weekly review workshops in a number of undergraduate Chemistry courses, conducted small group discussions to guide students through problem-solving and critical thinking exercises, graded problem sets and exams for 30-40 students
Summer Intern
Advisor: Dr. Michael GoldbergSupervised by: Ellese Carmona-Investigated the translational efficiency of modified mRNA untranslated regions compared with endogenous sequences using recombinant cloning tools and quantitative PCR
Summer Intern
Advisor: Dr. Jeffrey HubbellSupervised by: Dr. Daniel Bonner-Established a narrow range of per-particle concentration of antigen and adjuvant that provoked an optimal T cell response, using quantitative flow cytometry and enzyme-linked immunosorbent assay-Successfully functionalized polyethyleneglycol - polypropylenesulfide nanoparticles with antigen and adjuvant, and characterized the particles through dynamic light scattering, zeta potential, BCA & Iodine colorimetric assays
Chitavi (Chloe) Maulloo, Ph.D. education
Molecular Engineering, Immunology, Lymphatics
Bachelor Of Science (B.S.), Chemistry, Biology
Frequently asked questions about Chitavi (Chloe) Maulloo, Ph.D.
Quick answers generated from the profile data available on this page.
What company does Chitavi (Chloe) Maulloo, Ph.D. work for?
Chitavi (Chloe) Maulloo, Ph.D. works for IE Business School.
What is Chitavi (Chloe) Maulloo, Ph.D.'s role at IE Business School?
Chitavi (Chloe) Maulloo, Ph.D. is listed as IMBA Candidate at IE Business School.
What is Chitavi (Chloe) Maulloo, Ph.D.'s email address?
AeroLeads has found 1 work email signal at @uchicago.edu for Chitavi (Chloe) Maulloo, Ph.D. at IE Business School.
Where is Chitavi (Chloe) Maulloo, Ph.D. based?
Chitavi (Chloe) Maulloo, Ph.D. is based in New York, United States while working with IE Business School.
What companies has Chitavi (Chloe) Maulloo, Ph.D. worked for?
Chitavi (Chloe) Maulloo, Ph.D. has worked for Ie Business School, Scotiabank - Global Banking And Markets, Chardan, Jefferies, and Polsky Center At The University Of Chicago.
How can I contact Chitavi (Chloe) Maulloo, Ph.D.?
You can use AeroLeads to view verified contact signals for Chitavi (Chloe) Maulloo, Ph.D. at IE Business School, including work email, phone, and LinkedIn data when available.
What schools did Chitavi (Chloe) Maulloo, Ph.D. attend?
Chitavi (Chloe) Maulloo, Ph.D. holds Molecular Engineering, Immunology, Lymphatics from University Of Chicago.
What skills is Chitavi (Chloe) Maulloo, Ph.D. known for?
Chitavi (Chloe) Maulloo, Ph.D. is listed with skills including Cancer Immunology, Nanoparticles, Inorganic Synthesis, Lymphatics, Cell Culture, Matlab, Organic Chemistry, and Statistics.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial